Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 18;13:4305–4318. doi: 10.2147/OTT.S242854

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Wang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

LINC01614 abrogated the miR-383-mediated suppression on ADAM12. (A) Venn diagram. (B) Overall survival curves were evaluated by GEPIA algorithm. (C) cBioPortal algorithm analyzed the genetic alternation of related genes. (D) GEPIA algorithm analyzed ADAM12 expression in glioma samples from TCGA data. (E) qPCR determined ADAM12 levels in glioma specimens. (F) UALCAN algorithm analyzed ADAM12 expression across diverse cancer types. (G) GO and KEGG pathway analysis of ADAM12 positively correlated genes in glioma. (H) The predicted binding sites for miR-383 in ADAM12 mRNA 3ʹ-UTR. (I) Luciferase reporter assays. (J) qPCR determined LINC01614 and ADAM12 levels. (K) qPCR measured ADAM12 levels. (L) Western blot examined LINC01614 levels. **P < 0.01. n.s (not significant) represents “P > 0.05”.